Abstract OT2-11-07: Solti-1905. Elacestrant in preoperative setting, a window of opportunity study (ELIPSE trial)
María Vidal(Inserm), Meritxell Bellet(Vall d'Hebron Hospital Universitari), Xavier González(Breast Cancer Research Foundation), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Mireia Margelí Vila(Institut Català d'Oncologia), Fernando Salvador(Institute for Research in Biomedicine), Kepa Amillano(Hospital Universitari Sant Joan de Reus), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Aleix Prat(Hospital Clínic de Barcelona)
Cited by 4
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684